Dr. Gonzalez’s Best Cancer Cases as Presented to the National Cancer Institute
After just six years of practicing The Gonzalez Protocol®, a nutritional enzyme treatment for cancer, Nicholas Gonzalez, M.D. and his cancer patients experienced remarkable results. At this very early stage in his medical practice, Dr. Gonzalez was optimistic and believed that if he could prove that his protocol was effective for treating cancer, the NCI would support his nutritional cancer research. He complied his best cancer patient histories and presented his best 25 cancer patient cases to the National Cancer Institute (NCI) in 1993.
Proof of Concept demonstrates the importance of consistent good clinical outcomes of sufficient size. As Faiz Khan, M.D. remarks in the Preface, “this is all Gonzalez needed to show…and he did so beyond doubt.” As you will discover, there is no scientifically plausible explanation for this many cases of prolonged survival other than a treatment effect.
This book is Dr. Gonzalez’s original presentation including the appropriate patient medical records confirming each diagnosis. Cancers are independently diagnosed MRI and biopsy confirmed cases, many with metastases to lymph nodes, bone, liver, lungs or brain. This comprehensive presentation includes Dr. Gonzalez’s best cancer cases with 13 different types of cancer:
- breast cancer
- endometrial cancer
- adenoid cystic carcinoma
- head and neck cancer
- lung cancer
- ovarian cancer
- pancreatic cancer
- prostate cancer
- renal cell carcinoma
- thyroid cancer
Dr. Gonzalez’s book introduction states: “The great majority of these people presented with poor prognosis or terminal disease, and for most I provide evidence for reduction of tumor mass. In several cases, I document unusual tumor stabilization for periods of years, though not outright regression of disease.”
Dr. Linda Isaacs’ Foreword explains the circumstances surrounding this NCI Best Case Series in 1993, the resulting Gonzalez pancreatic cancer pilot study in 1999 and the NCI/NIH pancreatic cancer clinical trial in 2005.